Literature DB >> 17099095

Acute mountain sickness: medical problems associated with acute and subacute exposure to hypobaric hypoxia.

C Clarke1.   

Abstract

This article summarises the medical problems of travel to altitudes above 3000 m. These are caused by chronic hypoxia. Acute mountain sickness (AMS), a self limiting common illness is almost part of normal acclimatisation--a transient condition lasting for several days. However, in <2% of people staying above 4000 m, serious illnesses related to hypoxia develop--high altitude pulmonary oedema and cerebral oedema. These are potentially fatal but can be largely avoided by gradual ascent. Short vacations, pressure from travel companies and peer groups often encourage ascent to 4000 m more rapidly than is prudent. Sensible guidelines for ascent are outlined, clinical features, management and treatment of these conditions.

Entities:  

Mesh:

Year:  2006        PMID: 17099095      PMCID: PMC2660503          DOI: 10.1136/pgmj.2006.047662

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  7 in total

Review 1.  Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001.

Authors:  A J Pollard; S Niermeyer; P Barry; P Bärtsch; F Berghold; R A Bishop; C Clarke; S Dhillon; T E Dietz; A Durmowicz; B Durrer; M Eldridge; P Hackett; D Jean; S Kriemler; J A Litch; D Murdoch; A Nickol; J P Richalet; R Roach; D R Shlim; U Wiget; M Yaron; G Zubieta-Castillo; G R Zubieta-Calleja
Journal:  High Alt Med Biol       Date:  2001       Impact factor: 1.981

2.  Acute pulmonary edema of high altitude.

Authors:  C S HOUSTON
Journal:  N Engl J Med       Date:  1960-09-08       Impact factor: 91.245

Review 3.  Unraveling the mechanism of high altitude pulmonary edema.

Authors:  Robert B Schoene
Journal:  High Alt Med Biol       Date:  2004       Impact factor: 1.981

Review 4.  Current concept of chronic mountain sickness: pulmonary hypertension-related high-altitude heart disease.

Authors:  R L Ge; G Helun
Journal:  Wilderness Environ Med       Date:  2001       Impact factor: 1.518

5.  Mountain sickness, retinal haemorrhages, and acclimatisation on Mount Everest in 1975.

Authors:  C Clarke; J Duff
Journal:  Br Med J       Date:  1976-08-28

6.  Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT).

Authors:  Jeffrey H Gertsch; Buddha Basnyat; E William Johnson; Janet Onopa; Peter S Holck
Journal:  BMJ       Date:  2004-03-11

7.  Cerebral form of high-altitude illness.

Authors:  C S Houston; J Dickinson
Journal:  Lancet       Date:  1975-10-18       Impact factor: 79.321

  7 in total
  15 in total

1.  Effect of body position and oxygen tension on foramen ovale recruitment.

Authors:  Kayla L Moses; Arij G Beshish; Nicole Heinowski; Kim R Baker; David F Pegelow; Marlowe W Eldridge; Melissa L Bates
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-11-12       Impact factor: 3.619

2.  Carotid duplex ultrasound and transcranial Doppler findings in commercial divers and pilots.

Authors:  Banafshe Dormanesh; Kia Vosoughi; Fahimeh H Akhoundi; Masoud Mehrpour; Seyed-Mohammad Fereshtehnejad; Setareh Esmaeili; Azin Shafiee Sabet
Journal:  Neurol Sci       Date:  2016-07-26       Impact factor: 3.307

3.  Bioavailability, tissue distribution, and excretion characteristics of the novel carbonic anhydrase inhibitor tolsultazolamide in rats.

Authors:  Jin-da Wang; Yong-ping Shi; Jing Yin; Zhi-yuan Pan; Wen-yu Cui; Yan-fang Zhang; Hai Wang
Journal:  Acta Pharmacol Sin       Date:  2013-12-16       Impact factor: 6.150

4.  Behavioral recovery from acute hypoxia is reliant on leptin.

Authors:  Christina L Sherry; Jason M Kramer; Jason M York; Gregory G Freund
Journal:  Brain Behav Immun       Date:  2008-09-27       Impact factor: 7.217

5.  Preinduction of HSP70 promotes hypoxic tolerance and facilitates acclimatization to acute hypobaric hypoxia in mouse brain.

Authors:  Kuan Zhang; Tong Zhao; Xin Huang; Zhao-hui Liu; Lei Xiong; Ming-ming Li; Li-ying Wu; Yong-qi Zhao; Ling-ling Zhu; Ming Fan
Journal:  Cell Stress Chaperones       Date:  2008-12-23       Impact factor: 3.667

6.  M3: The military medicine module: A focussed competency-based program.

Authors:  Mahima Lall; Karuna Datta; Mr Arun Iyengar; Ashwani Shakya; Madhuri Kanitkar
Journal:  Med J Armed Forces India       Date:  2021-02-02

7.  Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial.

Authors:  Kyoung Heo; Joong Koo Kang; Chang Min Choi; Moo Song Lee; Kyoung Woo Noh; Soon Bae Kim
Journal:  J Korean Med Sci       Date:  2014-02-27       Impact factor: 2.153

8.  Effects of Hypobaric Hypoxia on Rat Retina and Protective Response of Resveratrol to the Stress.

Authors:  Xiaorong Xin; Hong Dang; Xiaojing Zhao; Haohao Wang
Journal:  Int J Med Sci       Date:  2017-08-17       Impact factor: 3.738

9.  Characteristics of a rat model of an open craniocerebral injury at simulated high altitude.

Authors:  An-Yong Yu; Quan-Hong Xu; Sheng-Li Hu; Fei Li; Yu-Jie Chen; Yi Yin; Gang Zhu; Jiang-Kai Lin; Hua Feng
Journal:  Neuroreport       Date:  2014-11-12       Impact factor: 1.837

Review 10.  Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: A joint statement by the European Society of Cardiology, the Council on Hypertension of the European Society of Cardiology, the European Society of Hypertension, the International Society of Mountain Medicine, the Italian Society of Hypertension and the Italian Society of Mountain Medicine.

Authors:  Gianfranco Parati; Piergiuseppe Agostoni; Buddha Basnyat; Grzegorz Bilo; Hermann Brugger; Antonio Coca; Luigi Festi; Guido Giardini; Alessandra Lironcurti; Andrew M Luks; Marco Maggiorini; Pietro A Modesti; Erik R Swenson; Bryan Williams; Peter Bärtsch; Camilla Torlasco
Journal:  Eur Heart J       Date:  2018-05-01       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.